Loading organizations...
§ Private Profile · Bagneux, Ile-de-France, France
A clinical-stage biopharmaceutical company developing epicutaneous immunotherapy via skin patches for food allergies and immune diseases.
DBV Technologies is a publicly traded biopharmaceutical company based in Montrouge, France, that develops epicutaneous immunotherapy via specialized skin patches to treat severe food allergies. The clinical-stage healthcare enterprise features a proprietary pipeline highlighted by Viaskin Peanut, which has successfully completed Phase 3 trials for pediatric peanut allergies, and Viaskin Milk, currently undergoing Phase 1 and Phase 2 trials. Operating with a dedicated workforce of 105 employees, the firm advances its innovative treatments through complex clinical research and regulatory processes toward potential commercialization. The biotechnology business was founded in 2002 by Pierre-Henri Benhamou, Christophe Dupont, and Stéphane Eigenmann to address the critical healthcare needs of patients with immune conditions. Today, the company operates under Chief Executive Officer Daniel Tassé, while founder Pierre-Henri Benhamou has received notable industry recognition from FARE for his clinical impact.
DBV Technologies has raised $25.6M across 1 funding round.
DBV Technologies has raised $25.6M in total across 1 funding round.
DBV Technologies has raised $25.6M across 1 funding round. Most recently, it raised $25.6M Series C in January 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2011 | $25.6M Series C | InnoBio Fund, Lundbeckfond Ventures | ALK Abello, Alto Invest, Apax Partners, CAP D \u00e9cisif, Creagro, Shire, Sofinnova Partners | Announced |
DBV Technologies has raised $25.6M in total across 1 funding round.
DBV Technologies's investors include InnoBio fund, Lundbeckfond Ventures, ALK Abello, Alto Invest, Apax Partners, Cap D \u00e9cisif, Creagro, Shire, Sofinnova Partners.